Tobacco
Compare Stocks
2 / 10Stock Comparison
XXII vs CGC
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
XXII vs CGC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Tobacco | Drug Manufacturers - Specialty & Generic |
| Market Cap | $119K | $122M |
| Revenue (TTM) | $19M | $294M |
| Net Income (TTM) | $-4M | $-327M |
| Gross Margin | -15.2% | 22.8% |
| Operating Margin | -62.0% | -24.1% |
| Total Debt | $4M | $348M |
| Cash & Equiv. | $7M | $114M |
XXII vs CGC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| 22nd Century Group,… (XXII) | 100 | 0.0 | -100.0% |
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XXII vs CGC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XXII carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.60, yield 100.0%
- Rev growth 48.1%, EPS growth 99.9%, 3Y rev CAGR -24.3%
- Lower volatility, beta 1.60, Low D/E 26.7%, current ratio 2.42x
CGC is the clearest fit if your priority is long-term compounding.
- -94.3% 10Y total return vs XXII's -100.0%
- -12.4% vs XXII's -99.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 48.1% revenue growth vs CGC's -9.5% | |
| Quality / Margins | -20.5% margin vs CGC's -111.0% | |
| Stability / Safety | Beta 1.60 vs CGC's 1.90, lower leverage | |
| Dividends | 100.0% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | -12.4% vs XXII's -99.8% | |
| Efficiency (ROA) | -14.2% ROA vs CGC's -29.5%, ROIC -81.4% vs -10.2% |
XXII vs CGC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
XXII vs CGC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CGC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CGC is the larger business by revenue, generating $294M annually — 15.2x XXII's $19M. XXII is the more profitable business, keeping -20.5% of every revenue dollar as net income compared to CGC's -111.0%. On growth, XXII holds the edge at +80.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $19M | $294M |
| EBITDAEarnings before interest/tax | -$11M | -$32M |
| Net IncomeAfter-tax profit | -$4M | -$327M |
| Free Cash FlowCash after capex | -$8M | -$86M |
| Gross MarginGross profit ÷ Revenue | -15.2% | +22.8% |
| Operating MarginEBIT ÷ Revenue | -62.0% | -24.1% |
| Net MarginNet income ÷ Revenue | -20.5% | -111.0% |
| FCF MarginFCF ÷ Revenue | -40.8% | -29.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +80.4% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +58.0% | +83.8% |
Valuation Metrics
XXII leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $118,791 | $122M |
| Enterprise ValueMkt cap + debt − cash | -$3M | $293M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.62x |
| Price / BookPrice ÷ Book value/share | 0.01x | 0.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
XXII leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
XXII delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-43 for CGC. XXII carries lower financial leverage with a 0.27x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), CGC scores 5/9 vs XXII's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -25.0% | -43.1% |
| ROA (TTM)Return on assets | -14.2% | -29.5% |
| ROICReturn on invested capital | -81.4% | -10.2% |
| ROCEReturn on capital employed | -72.6% | -12.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.27x | 0.72x |
| Net DebtTotal debt minus cash | -$3M | $235M |
| Cash & Equiv.Liquid assets | $7M | $114M |
| Total DebtShort + long-term debt | $4M | $348M |
| Interest CoverageEBIT ÷ Interest expense | -10.14x | -7.79x |
Total Returns (Dividends Reinvested)
CGC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CGC five years ago would be worth $45 today (with dividends reinvested), compared to $0 for XXII. Over the past 12 months, CGC leads with a -12.4% total return vs XXII's -99.8%. The 3-year compound annual growth rate (CAGR) favors CGC at -55.9% vs XXII's -99.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -94.6% | -5.0% |
| 1-Year ReturnPast 12 months | -99.8% | -12.4% |
| 3-Year ReturnCumulative with dividends | -100.0% | -91.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | -99.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -94.3% |
| CAGR (3Y)Annualised 3-year return | -99.0% | -55.9% |
Risk & Volatility
Evenly matched — XXII and CGC each lead in 1 of 2 comparable metrics.
Risk & Volatility
XXII is the less volatile stock with a 1.60 beta — it tends to amplify market swings less than CGC's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGC currently trades 47.5% from its 52-week high vs XXII's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.60x | 1.90x |
| 52-Week HighHighest price in past year | $455.40 | $2.38 |
| 52-Week LowLowest price in past year | $0.67 | $0.84 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +47.5% |
| RSI (14)Momentum oscillator 0–100 | 15.1 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 10.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
XXII is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $14.47 |
| # AnalystsCovering analysts | — | 26 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $25.42 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CGC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). XXII leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
XXII vs CGC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XXII or CGC a better buy right now?
For growth investors, 22nd Century Group, Inc.
(XXII) is the stronger pick with 48. 1% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XXII or CGC?
Over the past 5 years, Canopy Growth Corporation (CGC) delivered a total return of -99.
6%, compared to -100. 0% for 22nd Century Group, Inc. (XXII). Over 10 years, the gap is even starker: CGC returned -94. 3% versus XXII's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XXII or CGC?
By beta (market sensitivity over 5 years), 22nd Century Group, Inc.
(XXII) is the lower-risk stock at 1. 60β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 18% more volatile than XXII relative to the S&P 500. On balance sheet safety, 22nd Century Group, Inc. (XXII) carries a lower debt/equity ratio of 27% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — XXII or CGC?
By revenue growth (latest reported year), 22nd Century Group, Inc.
(XXII) is pulling ahead at 48. 1% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: 22nd Century Group, Inc. grew EPS 99. 9% year-over-year, compared to 37. 1% for Canopy Growth Corporation. Over a 3-year CAGR, CGC leads at -17. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XXII or CGC?
22nd Century Group, Inc.
(XXII) is the more profitable company, earning -28. 7% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps -28. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CGC leads at -43. 5% versus -64. 9% for XXII. At the gross margin level — before operating expenses — CGC leads at 29. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XXII or CGC?
In this comparison, XXII (100.
0% yield) pays a dividend. CGC does not pay a meaningful dividend and should not be held primarily for income.
07Is XXII or CGC better for a retirement portfolio?
For long-horizon retirement investors, 22nd Century Group, Inc.
(XXII) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (100. 0% yield). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XXII: -100. 0%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XXII and CGC?
These companies operate in different sectors (XXII (Consumer Defensive) and CGC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: XXII is a small-cap high-growth stock; CGC is a small-cap quality compounder stock. XXII pays a dividend while CGC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
- Sector: Consumer Defensive
- Market Cap > $20B
- Revenue Growth > 40%
- Dividend Yield > 40.0%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.